# Bioequivalence Study of Rivaroxaban From Repatoxaban 10 mg Tablets (Horus for Pharmaceutical Industries, Egypt) and Xarelto® 10 mg Tablets (Janssen Pharm., Licensed From: Bayer Healthcare, Germany)

> **NCT03071380** · PHASE1 · COMPLETED · sponsor: **Genuine Research Center, Egypt** · enrollment: 24 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Repatoxaban
- **DRUG:** Xarelto

## Key facts

- **NCT ID:** NCT03071380
- **Lead sponsor:** Genuine Research Center, Egypt
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02
- **Primary completion:** 2015-02
- **Final completion:** 2015-03
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2019-08-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03071380

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03071380, "Bioequivalence Study of Rivaroxaban From Repatoxaban 10 mg Tablets (Horus for Pharmaceutical Industries, Egypt) and Xarelto® 10 mg Tablets (Janssen Pharm., Licensed From: Bayer Healthcare, Germany)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03071380. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*